参考文献/References:
1 Robbins RJ. Pharmacology of bovine and human thyrotropin:an historical perspective[J]. Thyroid, 1999, 9(3):451-453.
2 Robbins RJ, Tuttle RM, Sonenberg M, et al. Radio-iodine ablation of thyroid remnants after preparation with recombinant human thyrotropin[J]. Thyroid, 2001, 11(6):865-869.
3 Robbins RJ, Larson SM, Sinha N, et al. A retrospective review of the effectiveness of recombinant human TSH as a preparation for radioiodine thyroid remnant ablation[J]. J Nucl Med, 2002, 43(7):1482-1488.
4 Pacini F, Molinaro E, Castagna MG, et al. Ablation of thyroid residues with 30mCi of 131I:a comparison in thyroid cancer patients prepared with recombinant human TSH or thyroid hormone withdrawal[J]. J Clin Endocrinol Metab, 2002, 87(6):4063-4068.
5 Barbaro D, Boni G, Meucci G, et al. Radio-iodine treatment with 30mCi after recombinant human thyrotropin stimulation in thyroid cancer:Effectiveness for postsurgical remnant ablation and possible role of iodine content in L-thyroxine in the outcome of ablation[J]. J Clin Endocrinol Metab, 2003, 89(6):4110-4115.
6 Luster M, Lassmann M, Haenscheid H, et al. Use of recombinant human thyrotropin before radio-iodine therapy in patients with advanced differentiated thyroid carcinoma[J]. J Clin Endocrinol Metab, 2000, 85(5):3640-3645.
7 Lippi F, Capezzone M, Angelini F, et al. Radio-iodine treatment of metastatic differentiated thyroid cancer in patients on L-thyroxine,using recombinant human TSH[J]. Eur J Endocrinol, 2001, 144(1):5-11.
8 Berg G, Lindstedt G, Suurkula M, et al. Radio-iodine ablation and therapy in differentiated thyroid cancer under stimulation with recombinant human thyroid-stimulating hormone[J]. J Endocrinol Inv, 2002, 25(1):44-52.
9 de Keizer B, Hoekstra A, Konijnenberg MW, et al. Bone marrow dosimetry and safety of high 131I activities given after recombinant human thyroid-stimulating hormone to treat metastatic differentiated thyroid cancer[J]. J Nucl Med, 2004, 45(9):1549-1554.
10 Santini F, Bottici V, Elisei R, et al. Cytotoxic effects of carboplatinum and epirubicin in the setting of an elevated serum thyrotropin for advanced poorly differentiated thyroid cancer[J]. J Clin Endocrinol Metab, 2002, 87(6):4160-4165.
11 Haugen BR. Management of the patient with progressive radioiodine non-responsive disease[J]. Semin Sur Oncol, 1999, 16(1):34-41.
12 Huysmans DA, Nieuwlaat WA, Erdtsieck R J, et al. Administration of a single low dose of recombinant human thyrotrepin significantly enhances thyroid radio-iodide uptake in nontoxic nodular goiter[J].J Clin Endocrinol Metab, 2000, 85(5):3592-3596.
13 Nieuwlaat WA, Huysmans DA, Van den Bosch HC, et al. Pretreatment with a single, low dose of recombinant human thyrotropin allows dose reduction of radio-iodine therapy in patients with nodular goiters[J]. J Clin Endocrinol Metab, 2003, 88(4):3121-3129.
14 Duick DS, Baskin HJ. Utility of recombinant human thyrotropin for augmentation of radio-iodine uptake and treatment of nontoxic and toxic multinodular goiters[J]. Endocr Pract, 2003, 9:204-209.
15 Silva MN, Rubio IG, Romao R, et al. Administration of a single dose of recombinant human thyrotrophin enhances the efficacy of radioiodine treatment of large compressive multinodular goitres[J]. Clin Endocrinol (Oxf), 2004, 60(3):300-308.
16 Nielsen VE, Bonnema SJ, Boel-Jorgensen H, et al. Recombinant human thyrotropin (rhTSH)markedly changes the 131I kinetics during 131I therapy of patients with nodular goiter.. An evaluation by a randomized double-blinded trial[J]. J Clin Endocrinol Metab, 2004, 90(1):79-83.
相似文献/References:
[1]白庆双,李宁,方佩华,等.人血清TRAb酶联免疫吸附试验检测在甲状腺疾病患者中的临床应用[J].国际放射医学核医学杂志,2014,38(2):80.[doi:10.3760/cma.j.issn.1673-4114.2014.02.003]
Bai Qingshuang,Li Ning,Fang Peihua,et al.The clinical application of human serum level of the TRAb measured by enzyme-linked immunosorbent assay in patients with thyroid diseases[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(2):80.[doi:10.3760/cma.j.issn.1673-4114.2014.02.003]
[2]刘丽波,罗云霄,王剑峰,等.《放射性甲状腺疾病诊断标准》解读[J].国际放射医学核医学杂志,2012,36(4):204.[doi:10.3760/cma.j.issn.1673-4114.2012.04.002]
LIU Li-bo,LUO Yun-xiao,WANG Jian-feng,et al.Explanation of Diagnostic Criteria for Radiation Thyroid Diseases[J].International Journal of Radiation Medicine and Nuclear Medicine,2012,36(2):204.[doi:10.3760/cma.j.issn.1673-4114.2012.04.002]
[3]张怡,袁卫红.硒与自身免疫性甲状腺疾病[J].国际放射医学核医学杂志,2012,36(6):376.[doi:10.3760/cma.j.issn.1673-4114.2012.06.013]
ZHANG Yi,YUAN Wei-hong.Selenium and autoimmune thyroid disease[J].International Journal of Radiation Medicine and Nuclear Medicine,2012,36(2):376.[doi:10.3760/cma.j.issn.1673-4114.2012.06.013]
[4]陈跃,黄占文,徐勇,等.加强多学科合作提高甲状腺疾病放射性核素治疗水平[J].国际放射医学核医学杂志,2008,32(6):357.
CHEN Yue,HUANG Zhan-wen,XU Yong,et al.Intellectual co-operation on improving radionuclide therapy of thyroid disease[J].International Journal of Radiation Medicine and Nuclear Medicine,2008,32(2):357.
[5]陆克义,李险峰.甲状腺疾病患者131I治疗后对他人的辐射危害评价[J].国际放射医学核医学杂志,2004,28(5):226.
LU Ke-yi,LI Xian-feng.Evaluation of radiation exposure from patients with thyroid disease by 131I therapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2004,28(2):226.
[6]卢倜章.131I治疗甲状腺疾病的研究趋向[J].国际放射医学核医学杂志,2000,24(3):97.
LU Ti-zhang.Current trend of research on 131I therapy for thyroid diseases[J].International Journal of Radiation Medicine and Nuclear Medicine,2000,24(2):97.
[7]卢倜章.核医学激素测定在甲状腺疾病中的应用[J].国际放射医学核医学杂志,1995,19(2):49.